Deep-Sequencing of HIV-1
|
|
|
- Estella Gardner
- 6 years ago
- Views:
Transcription
1 Deep-Sequencing of HIV-1 The quest for true variants Alexander Thielen, Martin Däumer
2 Limitations of drug resistance testing by standard-sequencing Blood plasma RNA extraction RNA Reverse Transcription/ Polymerase Chain Reaction cdna M Sample 2. Nested PCR PCR products (optional) Purification (optional) Sequencing Sensitivity Reaction for minor variants: >20% Purification Sequencer
3 Ultra-deep-sequencing Standard Sanger-sequencing...PQIYMDDHTRE... Ultra-deep-sequencing...PQIYMDDHTRE......PQIYMDDHTRE......PQIYVDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE...
4 454 Sequencing / Roche GS Junior System GS FLX+ System Illumina HiSeq Systems Genome analyzer IIx MiSeq, NextSeq Life Technologies SOLiD 5500 System SOLiD 5500xl System Ion Torrent PGM Proton Next Generation Sequencing, Amplified Single Molecule Sequencing Helicos Helicos Genetic Analysis System Pacific Biosciences PacBio RS Oxford Nanopore Technologies GridION System MinION Third Generation Sequencing, Single Molecule Sequencing
5 The players
6 Most important... iphone docking station
7 Specifications
8 MinION Nanopore technology
9 MinION Nanopore technology
10 MinION Nanopore technology HIV-1 pol amplicon, 1.35kb
11 outlook
12 Illumina systems
13 MiSeq sequencing instrument Illumina s benchtop sequencer easy sample preparation no homopolymer problems current specification: ~ up to 15 Gb output (10 x FLX+, >100 x 454 GS Junior) 2x20mio reads of up to 2x300 nts length 37h run time (2x250 nts)
14 MiSeq Personal Sequencing System
15 Library preparation using Nextera TM XT tagmentation Easy library preparation Fast - less than 20 minutes hands-on time Only 1ng DNA per sample needed Indices for up to 96 samples Normalization step included
16 Drug resistance testing using Illumina s MiSeq
17 Experimental setup HIV genome PRRT IN ENV whole genome
18 Fragmentation
19 putting things together mapping PRRT IN ENV Reference sequences
20 Coverage PR/RT ENV ~7500 full V3 loops
21 Reproducibility
22 PR/RT # resistance mutations found
23 PR/RT resistance interpretation ATV/r limited susceptibility Intermediate Resistance % 2% 5% 10% 15% 20% SANGER interpretation according to
24 Number of sequencing errors, substitutions, deletions, and insertions Archer J et al., 2012, PLoS ONE 7: e doi: /journal.pone
25 Workflow NGS Library preparation: fragmentation & indexing RNA/DNA Total NA extraction rt-pcr/ nested pcr Sanger Sequencing reaction Taq-cycle reaction, sequencing analysis analysis
26 Workflow NGS RNA/DNA Total NA extraction Sanger Library preparation: fragmentation & indexing Sequencing reaction analysis PCR errors Sequencing errors rt-pcr/ nested pcr RNA vs. DNA: viable vs non-viable PCR errors, recombination Potential error sources editing Taq-cycle reaction, sequencing analysis
27 PCR errors in clones 7,00% 6,00% 5,00% 4,00% 3,00% 2,00% 1,00% 0,00% I47V I50V N83D I84V D30N G73D L76V G48V K20M M46L I54M T74P V82L L89V K20V G73T V82C M230V D67G K219E K219R K70E K101E V118I V179I V189I H221Y K238T T215S T215N A B C D E1 E2 V179D K219N A98G Y115F K101Q F227C K101H P225H T215F K103S T69D T215D V179T Y181I A
28 PCR errors in clones
29 Effect of high fideltity enzymes 3,50% 3,00% 2,50% 2,00% 1,50% 1,00% 0,50% 0,00% G48V N83D I50V F53L I54V G73D L10I K20M M46L I50L K43T I54L L10V G48A G73T V82M D67G M230V E138G P225H Y188H V75A V106A V90I G190E E138K D67N V179E Qiagen One step RT-PCR kit / HotStarTaq Invitrogen One step RT-PCR Superscript III / HiFi Platinum Taq M41L L74V L74I Y115F T215N K101Q V179I K101P T215F G190Q V75M T215Y Q151M K103S V179F Y181I
30 Ultra-deep sequencing of proviral DNA
31 C.,J. *1980 1st line ART: TDF/FTC/EFV Resistance test from proviral DNA Viruslast Kop/ml CD4 + /µl
32 Proviral DNA
33 Plasmavirus RNA
34 C.,J. *1980 Proviral DNA Standard Sanger
35 ... but things may turn out diffenrently...
36 Resistence testing from proviral DNA and low-abundance variants D
37 Deep-Sequencing of HIV-1 The quest for true proviral variants Alexander Thielen
38 Resistance testing from proviral DNA viral archive interesting what about defective viruses? => not preferred but sometimes required
39 Resistance testing from proviral DNA what means defective? stop codons => definitively hypermutated => probably other suggestions? do we see these viruses in our data? do we have a big problem?
40 Stop codons in the routine samples: RNA : 528 DNA: 169 samples with stop codons: cutoff DNA RNA 1% % % 2% % % 5% % % 10% % % 15% % % 20% % % 30% % %
41 Where are the stop codons are coming from? PR: W42* RT: W88*, W153*, W229*, W266*, W212*, W71*, W212*, W252*, W153*, W239*, W24* TAG HXB2 reference codon: TGG TGA stop codons mostly: TAG TAA Apobec? Apobec3F: GA AA Apobec3G GG AG, further preference for TGG, TGGG motifs!
42 Are there further motifs found in DNA? other reading frames, e.g. ATGG ATAG (M I) odds ratio DNA / RNA > cutoff, N at least 5: PR: 42*, 90M, 73S,... RT: 135V, 184V, 88*, 51R, 41L, 153*, 36A*, 212*, 230I, 70R, 196R, 35M, 266*, 16I, 210W, 41I, 45E,... can these be explained by Apobec? not all, e.g. M184V: ATG GTG
43 Covariation analysis Are there further motifs found in DNA?
44 Covariation analysis Are there further motifs found in DNA? M184V, 41L, 70R, 210W, 181C, 215Y, 65R, 190A, PR-90M, 219Q, 215F,... no G A! Wx*, 51R, 230I, 196R, 16I, 41I, 45E, 184I, 190R, 276I, 186N,... G A!
45 Covariation within patient sample D 190R 3.6% 230I 3.6% 184I 3.5% 252* 3.35% 153* 4.35% 230I w/o 252* 1.23% 184I w/o 153* 1.38% 190R w/o 153* 1.62%
46 Covariation within patient sample D 190R 8.95% 230I 9.35% 184I 0.17%? 252* 0.52% 153* 0.52% 230I w/o 252* 9.22% also no correlations with other stop-codons but high correlation between 190R and 230I
47 Covariation within patient sample R 0.37% 230I 4.31% 184I 0.24% no correlations with stop-cluster mutations
48 Acknowledgments Kirsten Becker Nina Engel Anna Memmer Benjamin Racké Bettina Spielberger Steffi Wenzel Bernhard Thiele
New technologies reaching the clinic
New technologies reaching the clinic Martin Däumer May 31, 2018 Deep-sequencing Standard Sanger-sequencing...PQIYMDDHTRE... Ultra-deep-sequencing...PQIYMDDHTRE......PQIYMDDHTRE......PQIYVDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE......PQIYMDDHTRE...
HIV-1 resistance testing from proviral DNA
HIV-1 resistance testing from proviral DNA Alexander Thielen AREVIR 2018 Resistance testing from proviral DNA? amount of samples with low viral loads increasing desire to switch under successful therapy
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European
To test the possible source of the HBV infection outside the study family, we searched the Genbank
Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),
Alexander Thielen 16th European Meeting on HIV & Hepatitis
Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA First Results from the LOWER Study Alexander Thielen, Martin
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared
DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING. John Archer. Faculty of Life Sciences University of Manchester
DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING John Archer Faculty of Life Sciences University of Manchester HIV Dynamics and Evolution, 2008, Santa Fe, New Mexico. Overview
History (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
ICAAC/IDSA DC, Oct. 26, 2008
Tenofovir (TDF)- or Abacavir (ABC)-selected Minority Subpopulations in Viremic Subjects Detected by Ultra-deep Sequencing R. T. D Aquila 1, E. Rouse 2, J. Horton 2, A. Kheshti 1,3, S. Raffanti 1,3, K.
A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples
A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples Sona Pekova, MD., PhD. Chambon Ltd., Laboratory for molecular diagnostics, Prague, Czech
modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
Resistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared by: Brian
Best practice DNA prep for SMRT. Olga Vinnere Pettersson, PhD Project coordinator NGI-Sweden / SciLifeLab (UU)
Best practice DNA prep for SMRT Olga Vinnere Pettersson, PhD Project coordinator NGI-Sweden / SciLifeLab (UU) National Genomics Infrastructure - Sweden NGI Stockholm NGI Uppsala NGI staff: 60-70 FTE, including
Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR
Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
Improving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen
Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance
NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
Performance Characteristics BRCA MASTR Plus Dx
Performance Characteristics BRCA MASTR Plus Dx with drmid Dx for Illumina NGS systems Manufacturer Multiplicom N.V. Galileïlaan 18 2845 Niel Belgium Table of Contents 1. Workflow... 4 2. Performance Characteristics
Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays
Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays Christian Pou 1, Rocío Bellido 1, Francisco M. Codoñer 1, Alexander Thielen 3, Cecilia Cabrera 1, Judith Dalmau
AIDS Research and Therapy. Open Access RESEARCH
https://doi.org/.1186/s12981-18-26-y AIDS Research and Therapy RESEARCH Open Access Characterization of minority HIV 1 drug resistant variants in the United Kingdom following the verification of a deep
Figure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T
Figure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T cells, the RNA genomes with all modifications are generated
Introduction to Systems Biology of Cancer Lecture 2
Introduction to Systems Biology of Cancer Lecture 2 Gustavo Stolovitzky IBM Research Icahn School of Medicine at Mt Sinai DREAM Challenges High throughput measurements: The age of omics Systems Biology
Received 21 November 2005/Returned for modification 20 January 2006/Accepted 27 March 2006
JOURNAL OF CLINICAL MICROBIOLOGY, June 2006, p. 1930 1943 Vol. 44, No. 6 0095-1137/06/$08.00 0 doi:10.1128/jcm.02415-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Evaluation
Clinical utility of NGS for the detection of HIV and HCV resistance
18 th Annual Resistance and Antiviral Therapy Meeting v Professor Janke Schinkel Academic Medical Centre, Amsterdam, The Netherlands Thursday 18 September 2014, Royal College of Physicians, London Clinical
NGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.
![172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.](/thumbs/82/85138523.jpg "172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.")
5 5 5 5 A MgCl 2 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] B 172R 172K TAM-2/172R TAM-2/172K AZT concentration [nm] ATP + ATP - Supplemental Figure 1. Primer extension of HIV-1 RT polymorphisms
Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq
Dudley et al. Retrovirology ( DOI 10.1186/s12977-014-0122-8 RESEARCH Open Access Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations
Introduction to the Impact of Resistance in Hepatitis C
Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st, 2017 1 AbbVie disclosures This is an Abbvie sponsored
Personalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
Analysis of the genetic diversity of influenza A viruses using next-generation DNA sequencing
See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/273470093 Analysis of the genetic diversity of influenza A viruses using next-generation DNA
Diagnosis of infectious diseases and confirmation of diagnosis. Molecular epidemiology of emerging/re-emerging pathogens
LA PREPARAZIONE E LA RISPOSTA ALLE EMERGENZE INFETTIVE Padova, 20 settembre 2012 Laboratory advanced technologies in the support of Public Health interventions in infectious disease emergencies Prof. Giorgio
Ambient temperature regulated flowering time
Ambient temperature regulated flowering time Applications of RNAseq RNA- seq course: The power of RNA-seq June 7 th, 2013; Richard Immink Overview Introduction: Biological research question/hypothesis
Supplementary Figure 1 Weight and body temperature of ferrets inoculated with
Supplementary Figure 1 Weight and body temperature of ferrets inoculated with A/Anhui/1/2013 (H7N9) influenza virus. (a) Body temperature and (b) weight change of ferrets after intranasal inoculation with
Antiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
NEXT GENERATION SEQUENCING OPENS NEW VIEWS ON VIRUS EVOLUTION AND EPIDEMIOLOGY. 16th International WAVLD symposium, 10th OIE Seminar
NEXT GENERATION SEQUENCING OPENS NEW VIEWS ON VIRUS EVOLUTION AND EPIDEMIOLOGY S. Van Borm, I. Monne, D. King and T. Rosseel 16th International WAVLD symposium, 10th OIE Seminar 07.06.2013 Viral livestock
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
Simple, rapid, and reliable RNA sequencing
Simple, rapid, and reliable RNA sequencing RNA sequencing applications RNA sequencing provides fundamental insights into how genomes are organized and regulated, giving us valuable information about the
HIV and drug resistance Simon Collins UK-CAB 1 May 2009
HIV and drug resistance Simon Collins UK-CAB 1 May 2009 slides: thanks to Prof Clive Loveday, Intl. Clinical Virology Centre www.icvc.org.uk Tip of the iceberg = HIV result, CD4, VL Introduction: resistance
Accel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation
Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation By: Blake M. Hauser Senior Honors Thesis Department of Biology College of Arts and Sciences The University of North Carolina
COMPARISON OF HIV DRUG-RESISTANT MUTANT DETECTION BY NGS WITH AND WITHOUT UNIQUE MOLECULAR IDENTIFIERS (UMI)
COMPARISON OF HIV DRUG-RESISTANT MUTANT DETECTION BY NGS WITH AND WITHOUT UNIQUE MOLECULAR IDENTIFIERS (UMI) Kevin D McCormick; Kerri J Penrose; Rahil Sethi; Jacob Waldman; William Schwarzmann; Uma Chandran;
Table S1. Primers and PCR protocols for mutation screening of MN1, NF2, KREMEN1 and ZNRF3.
Table S1. Primers and PCR protocols for mutation screening of MN1, NF2, KREMEN1 and ZNRF3. MN1 (Accession No. NM_002430) MN1-1514F 5 -GGCTGTCATGCCCTATTGAT Exon 1 MN1-1882R 5 -CTGGTGGGGATGATGACTTC Exon
CRISPR/Cas9 Enrichment and Long-read WGS for Structural Variant Discovery
CRISPR/Cas9 Enrichment and Long-read WGS for Structural Variant Discovery PacBio CoLab Session October 20, 2017 For Research Use Only. Not for use in diagnostics procedures. Copyright 2017 by Pacific Biosciences
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate
Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
Evaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
LAL: significato clinico e biologico delle mutazioni di Bcr-Abl
LAL: significato clinico e biologico delle mutazioni di Bcr-Abl Simona Soverini Dipartimento di Ematologia e Scienze Oncologiche L. e A. Seràgnoli Università di Bologna The vast majority of Ph+ ALL patients
DNA-seq Bioinformatics Analysis: Copy Number Variation
DNA-seq Bioinformatics Analysis: Copy Number Variation Elodie Girard elodie.girard@curie.fr U900 institut Curie, INSERM, Mines ParisTech, PSL Research University Paris, France NGS Applications 5C HiC DNA-seq
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
Iso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing
Iso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing PacBio Americas User Group Meeting Sample Prep Workshop June.27.2017 Tyson Clark, Ph.D. For Research Use Only. Not
HIV DNA Genotyping by UDS compared with cumulative HIV RNA Genotypes in Pretreated Patients
HIV DNA Genotyping by UDS compared with cumulative HIV RNA Genotypes in Pretreated Patients Mathieu BLOT, Yannis DUFFOURD, Hélène GIRAUDON, Emilie TISSERAND, Arnaud SALMON-ROUSSEAU, Sophie MAHY, Marielle
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing Karl V. Voelkerding, MD Professor of Pathology University of Utah Medical
Monitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab
Monitoring for Drug Resistance by Genotyping Urvi M Parikh, PhD MTN Virology Core Lab Outline What is Drug Resistance? Genotyping Algorithm Standard vs Sensitive Resistance Testing Sequencing Protocols
ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
Molecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The NSABP Foundation
Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
The Sequencing Continuum for Clinical Research: From Sanger to Next Gen Webinar 12 March 2014
The Sequencing Continuum for Clinical Research: From Sanger to Next Gen Webinar 12 March 2014 [0:00:00] Slide 1 Sean Sanders: Hello everyone and a very warm welcome to the Science/AAAS webinar. My name
Relative activity (%) SC35M
a 125 Bat (H17N) b 125 A/WSN (H1N1) Relative activity (%) 0 75 50 25 Relative activity (%) 0 75 50 25 0 Pos. Neg. PA PB1 Pos. Neg. NP PA PB1 PB2 0 Pos. Neg. NP PA PB1 PB2 SC35M Bat Supplementary Figure
Implementation of BRCA Oncomine panel for germline and somatic variant analysis
Tagliafico ESHG 2017.pptm 3.2% 03/03/2017 Implementation of BRCA Oncomine panel for germline and somatic variant analysis Enrico Tagliafico MD, PhD, Modena, Italy Center for Genome Research University
AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
SUPPLEMENTARY INFORMATION
doi:10.1038/nature13898 Supplementary Information Table 1 Kras mutation status of carcinogen-induced mouse lung adenomas Tumour Treatment Strain Grade Genotype Kras status (WES)* Kras status (Sanger) 32T1
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
Antiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh
Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these
Please Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
Accessing and Using ENCODE Data Dr. Peggy J. Farnham
1 William M Keck Professor of Biochemistry Keck School of Medicine University of Southern California How many human genes are encoded in our 3x10 9 bp? C. elegans (worm) 959 cells and 1x10 8 bp 20,000
HBV. Next Generation Sequencing, data analysis and reporting. Presenter Leen-Jan van Doorn
HBV Next Generation Sequencing, data analysis and reporting Presenter Leen-Jan van Doorn HBV Forum 3 October 24 th, 2017 Marriott Marquis, Washington DC www.forumresearch.org HBV Biomarkers HBV biomarkers:
Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) DNA Supplementary Materials
Transmission Fitness of Drug- Resistant HIV Revealed in the United States National Surveillance System
Transmission Fitness of Drug- Resistant HIV Revealed in the United States National Surveillance System Joel O. Wertheim 1,2, Alexandra M. Oster 3, Jeffrey A. Johnson 3, William M. Switzer 3, Neeraja Saduvala
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
Characterizing intra-host influenza virus populations to predict emergence
Characterizing intra-host influenza virus populations to predict emergence June 12, 2012 Forum on Microbial Threats Washington, DC Elodie Ghedin Center for Vaccine Research Dept. Computational & Systems
The Journal of Infectious Diseases BRIEF REPORT
The Journal of Infectious Diseases BRIEF REPORT Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1 Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger
Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research
Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Application Note Authors John McGuigan, Megan Manion,
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
P. Tang ( 鄧致剛 ); PJ Huang ( 黄栢榕 ) g( ); g ( ) Bioinformatics Center, Chang Gung University.
Databases and Tools for High Throughput Sequencing Analysis P. Tang ( 鄧致剛 ); PJ Huang ( 黄栢榕 ) g( ); g ( ) Bioinformatics Center, Chang Gung University. HTseq Platforms Applications on Biomedical Sciences
Norgen s HIV Proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad T1000 Cycler
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product# 33840 Product Insert Intended
Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2007, p. 550 578 Vol. 20, No. 4 0893-8512/07/$08.00 0 doi:10.1128/cmr.00017-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Clinical Significance
Variation of Human Immunodeficiency Virus Type-1 Reverse Transcriptase within the Simian Immunodeficiency Virus Genome of RT-SHIV
Variation of Human Immunodeficiency Virus Type-1 Reverse Transcriptase within the Simian Immunodeficiency Virus Genome of RT-SHIV Debra A. Wadford, University of California Davis Robert C. Kauffman, University
Diagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
HIV-1 acute infection: evidence for selection?
HIV-1 acute infection: evidence for selection? ROLLAND Morgane University of Washington Cohort & data S6 S5 T4 S4 T2 S2 T1 S1 S7 T3 DPS (days post symptoms) 3 (Fiebig I) 7 (Fiebig I) 13 (Fiebig V) 14 (Fiebig
Viral genome sequencing: applications to clinical management and public health. Professor Judy Breuer
Viral genome sequencing: applications to clinical management and public health Professor Judy Breuer Why do whole viral genome sequencing Genome sequencing allows detection of multigenic resistance in
Prevalence of HPV-16 genomic variant carrying a 63-bp duplicated sequence within the E1 gene in Slovenian women
Prevalence of HPV-16 genomic variant carrying a 63-bp duplicated sequence within the E1 gene in Slovenian women K E Y WORDS HPV-16, cervical cancer, E6-T350G variant A BSTRACT High-risk HPV, particularly
Recombinant Protein Expression Retroviral system
Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential
High resolution HLA typing from second generation sequencing data
High resolution HLA typing from second generation sequencing data This thesis is presented for the degree of Doctor of Philosophy Murdoch University Don Cooper Institute for Immunology and Infectious Diseases
Innovative diagnostics for HIV, HBV and HCV
Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is
Favorable outcomes of pediatric second-line protease inhibitor-based antiretroviral treatment in Uganda
Favorable outcomes of pediatric second-line protease inhibitor-based antiretroviral treatment in Uganda Ragna S. BOERMA, Cissy M. KITYO, T. Sonia BOENDER, Elizabeth KAUDHA, Joshua KAYIWA, Victor MUSIIME,
Norgen s HIV proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad icycler
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com HIV Proviral DNA PCR Kit Product # 33840 Product Insert Background Information
Proposed EPPO validation of plant viral diagnostics using next generation sequencing
Proposed EPPO validation of plant viral diagnostics using next generation sequencing Ian Adams, Ummey Hany, Rachel Glover, Erin Lewis, Neil Boonham, Adrian Fox Adoption of Next Generation Sequencing for
Phylogenomics. Antonis Rokas Department of Biological Sciences Vanderbilt University.
Phylogenomics Antonis Rokas Department of Biological Sciences Vanderbilt University http://as.vanderbilt.edu/rokaslab High-Throughput DNA Sequencing Technologies 454 / Roche 450 bp 1.5 Gbp / day Illumina
Characterization and data assessment of NGS-based genotyping using VQA HIVDR proficiency panels
Characterization and data assessment of NGS-based genotyping using VQA HIVDR proficiency panels Hezhao Ji / Emma R Lee National HIV and Retrovirology Laboratories National Microbiology Laboratory at JC
Supplementary Figure 1
Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the